Clinical trial · Interventional
Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A variety of in vivo experimental models have been established for the studies of human cancer using both cancer cell lines and patient-derived xenografts (PDXs). In order to meet the aspiration of precision medicine, the in vivo murine models have been widely adopted. However, common constraints such as high cost, long duration of experiments, and low engraftment efficiency remained to be resolved. The chick embryo chorioallantoic membrane (CAM) is an alternative model to overcome some of these limitations. The chick CAM is shown to be a robust model for both the inoculation of cell lines and grafting of patient tumors for drug therapy evaluations and target genes/pathways analysis. The start-up INOVOTION has developed a unique, highly sensitive and reproducible CAM assay to graft human cancer cells/tumors in the chicken egg environment. INOVOTION's technology was validated for over 55 human tumor cell lines, including carcinomas, gliomas and melanomas, as well as over 30 reference drugs currently on the market. At INOVOTION, the graft of human cancer cells on the chicken CAM is currently conducted manually. To scale-up, the process was recently automated. The automation performance was assessed on cancer cells lines. The objective of this study is to demonstrate that the automation of the INOVOTION process enables tumors' proliferation using patient samples (from tumor samples or circulating tumor cells) as grafting material.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cancer Metastatic | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient sampling. | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 6 cohort
- description
- Prostate Cohorte : Castrate resistant metastatic prostate cancer patient Breast cohort : HER2+ ou RH+ metastatic breast cancer patient Lung cohort : Non-small cell lung metastatic lung cancer patient Ovarian cohort : Ovarian cancer with peritoneal carcinomatosis Colorectal cohort : Colorectal cancer with peritoneal carcinomatosis Gastric cancer : Gastric cancer with peritoneal carcinomatosis
- interventionNames
- Procedure: Patient sampling.
Primary outcomes (1)
- measure
- The main primary endpoint will be reached, if the xenograft rate using patients' samples is ≥ 50% with the INOVOTION automated process.
- timeFrame
- The sample outcome will be measured 19 days after egg engraftment.
- description
- A xenograft will be considered successful if proliferating human material is found in at least one of the egg engrafted with the patient sample (one patient sample being able to be used to engraft several eggs). Success = at least one successful xenograft on all engrafted eggs with a patient sample Failed: 0 successful xenograft on all engrafted eggs with a patient sample
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
* Inclusion Criteria for all cohorts \* : * Age \> 18 * Signed consent * Inclusion criteria for the "Prostate" cohort: * prostate adenocarcinoma histologically proven * metastatic situation * at least 2 metastatic sites * Evolutionary disease that requires a new treatment * Inclusion criteria for the "Breast" cohort: * HER2+ or RH+ breast adenocarcinoma histologically proven * metastatic situation * at least 2 metastatic sites * Evolutionary disease that requires a new treatment * Inclusion criteria for the "Lung" cohort: * Non Small Lung cancer histologically proven * metastatic situation * at least 2 metastatic sites * Evolutionary disease that requires a new treatment * Inclusion criteria for "Ovarian" cohort: * Ovarian cancer histologically proven * Presence of peritoneal carcinomatosis (stage IIIC or IV); with or without presence of peritoneal fluid * Inclusion criteria for "Colo-Rectal" cohort: * Colo-rectal cancer histologically proven * Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid * Evolutionary disease that requires a new treatment * Inclusion criteria for "Gastric" cohort: * Gastric cancer histologically proven * Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid * Exclusion Criteria for all cohorts \* : * Weight \<50kg * Parallel participation in a doubled blinded study * Brain or ganglionary metastasis only
References
Publications (0)
Data not yet available